Breaking News Instant updates and real-time market news.

GRUB

GrubHub

$54.70 /

+6.075 (+12.49%)

, UBER

Uber

$33.95 /

+1.14 (+3.47%)

09:04
01/09/20
01/09
09:04
01/09/20
09:04

Uber the most likely buyer if GrubHub gets sold, says JMP Securities

After The Wall Street Journal reported yesterday that Grubhub (GRUB) has hired advisors to consider potential strategic options, JMP Securities analyst Ronald Josey said he is "not surprised" given his view that Grubhub has meaningful strategic value. Should Grubhub be acquired, he views Uber (UBER) as the most likely acquirer, but he also believes other bidders could include DoorDash, Amazon (AMZN), Booking (BKNG) and possibly some European food delivery companies. Using Takeaway.com's announced acquisition of Just Eat as a proxy would imply Grubhub could be acquired for about $70 per share, but Josey believes Grubhub could be acquired at a higher multiple given its position in the U.S. market and strategic value. He maintains a Market Perform rating on Grubhub shares.

GRUB

GrubHub

$54.70 /

+6.075 (+12.49%)

UBER

Uber

$33.95 /

+1.14 (+3.47%)

AMZN

Amazon.com

$1,891.30 /

-15.105 (-0.79%)

BKNG

Booking Holdings

$2,060.29 /

-6.75 (-0.33%)

  • 10

    Feb

GRUB GrubHub
$54.70 /

+6.075 (+12.49%)

01/09/20 Deutsche Bank
GrubHub could be worth 'substantially higher' in buyout, says Deutsche Bank
01/09/20 Wedbush
GrubHub price target raised to $45 from $30 at Wedbush
01/08/20 Stifel
GrubHub's reported strategic review 'seems prudent,' says Stifel
01/06/20 Credit Suisse
GrubHub price target raised to $52 from $42 at Credit Suisse
UBER Uber
$33.95 /

+1.14 (+3.47%)

01/02/20 RBC Capital
Accelerating Netflix subs, Uber profitability among RBC's top 10 surprise list
AMZN Amazon.com
$1,891.30 /

-15.105 (-0.79%)

01/09/20 Bernstein
Bernstein starts Spotify at Underperform on 'overly optimistic' expectations
01/09/20 BofA
Amazaon, Wix.com, & SVB Financial added to US 1 List at BofA
01/07/20 MKM Partners
MKM Partners says Amazon remains #1 stock pick for 2020
BKNG Booking Holdings
$2,060.29 /

-6.75 (-0.33%)

12/30/19 Guggenheim
Simple look at Booking may overstate Expedia cost cut potential, says Guggenheim
12/24/19 SunTrust
Booking Holdings room night growth tracking above consensus, says SunTrust
12/20/19 JMP Securities
Booking Holdings price target raised to $2,300 from $2,240 at JMP Securities

TODAY'S FREE FLY STORIES

Upgrade
Wolters Kluwer upgraded to Neutral from Underweight at JPMorgan » 21:33
02/26/20
02/26
21:33
02/26/20
21:33
WTKWY

Wolters Kluwer

$0.00 /

+ (+0.00%)

JPMorgan analyst Daniel…

JPMorgan analyst Daniel Kerven upgraded Wolters Kluwer to Neutral from Underweight with a EUR 70 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
BioMarin firing on all cylinders, says Piper Sandler » 20:42
02/26/20
02/26
20:42
02/26/20
20:42
BMRN

BioMarin

$91.40 /

+0.37 (+0.41%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Global Blood Therapeutics Oxbryta results 'encouraging', says Piper Sandler » 20:36
02/26/20
02/26
20:36
02/26/20
20:36
GBT

Global Blood Therapeutics

$64.59 /

+0.11 (+0.17%)

Piper Sandler analyst…

Piper Sandler analyst Danielle Brill keeps her Overweight rating and $120 price target on Global Blood Therapeutics after its Q4 results. The analyst notes that the management's commentary suggests that Oxbryta launch is going well with $2.1M in contributed revenue, even though it was only available for a couple of weeks in December. Brill adds that she continues to view the demand for Oxbryta as high, and she is not concerned with the management holding off on providing hard launch metrics.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Innovative Industrial Properties reports Q4 EPS 78c, one estimate 57c » 20:31
02/26/20
02/26
20:31
02/26/20
20:31
IIPR

Innovative Industrial Properties

$96.08 /

-0.385 (-0.40%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Stepan Company updates on Millsdale Plant incident » 20:29
02/26/20
02/26
20:29
02/26/20
20:29
SCL

Stepan Company

$92.69 /

-0.82 (-0.88%)

On February 20, 2020, the…

On February 20, 2020, the fompany announced that its Millsdale plant was forced to stop production of Phthalic Anhydride and Surfactants due to power outage-related operational issues that impacted the site's waste water treatment plant. As a result, the company declared force majeure for the supply of PA and certain Surfactant product lines.

Earnings
Notable companies reporting before tomorrow's open » 20:25
02/26/20
02/26
20:25
02/26/20
20:25
BUD

AB InBev

$66.35 /

-0.5 (-0.75%)

, KDP

Keurig Dr Pepper

$28.72 /

-0.205 (-0.71%)

, BBY

Best Buy

$82.23 /

+0.365 (+0.45%)

, DISCA

Discovery

$26.50 /

-0.925 (-3.37%)

, NLSN

Nielsen

$20.29 /

-0.13 (-0.64%)

, SERV

ServiceMaster

$33.81 /

-2.515 (-6.92%)

, JCP

J.C. Penney

$0.73 /

+0.034 (+4.90%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include AB InBev (BUD), consensus $1.05... Keurig Dr Pepper (KDP), consensus 35c... Best Buy (BBY), consensus $2.75... Discovery (DISCA), consensus 93c... Nielsen (NLSN), consensus 42c... ServiceMaster (SERV), consensus 19c... J. C. Penney (JCP), consensus (6c).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
FreightCar America reports Q4 EPS (75c), two estimates (59c) » 20:07
02/26/20
02/26
20:07
02/26/20
20:07
RAIL

FreightCar America

$1.45 /

-0.07 (-4.61%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
Earnings
Cactus reports Q4 adj. EPS 38c, consensus 36c » 20:02
02/26/20
02/26
20:02
02/26/20
20:02
WHD

Cactus

$25.45 /

-0.8 (-3.05%)

Reports Q4 revenue…

Reports Q4 revenue $140.2M, consensus $141.69M. Reports Q4 adj. EBITDA $48.4M vs. $58.8M last year. CEO Scott Bender says: "2019 was a record year for Cactus. Despite a larger than anticipated decline in the overall U.S. onshore rig count during the fourth quarter, our results were generally consistent with our expectations. The overall margin profile of the business remained strong, notwithstanding the typical seasonal slowdown in Field Service due in part to lower completions activity driven by E&P budget exhaustion. The quarter highlighted the Company's ability to generate significant free cash flow, with cash growing by over $35 million during the period, net of nearly $7 million in dividend payments and associated distributions. Looking to the first quarter of 2020, customers have again shown a willingness to quickly increase completion activity following the reset of budgets in January. We currently anticipate that revenue across all our business lines will increase relative to the fourth quarter of 2019. Additionally, the adoption of our new frac innovations has continued to progress during the first quarter. During our time as a public entity, Cactus has demonstrated its ability to perform well in the face of a challenging market environment. Going forward, we believe the capital-light nature of the business will further separate us from our peers, and we expect 2020 to highlight our ability to gain market share at attractive margins and generate substantial free cash flow."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
SJW Group sees FY20 EPS $2.25-$2.35, consensus $2.31  19:59
02/26/20
02/26
19:59
02/26/20
19:59
SJW

SJW Group

$69.38 /

+0.24 (+0.35%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
SJW Group reports Q4 EPS 34c ex expenses, consensus 41c » 19:58
02/26/20
02/26
19:58
02/26/20
19:58
SJW

SJW Group

$69.38 /

+0.24 (+0.35%)

Reports Q4 revenue…

Reports Q4 revenue $125.8M, consensus $121.28M. SJW Group President & CEO Eric Thornburg stated "Our transformative merger with CTWS positions us for future growth and success. We are incredibly proud of this achievement. We are also very pleased to begin to move forward with a focus on realizing the combination's benefits for all of our stakeholders."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
SPDR Gold Shares holdings fall to 935.70MT from 940.09MT » 19:53
02/26/20
02/26
19:53
02/26/20
19:53
GLD

SPDR Gold Shares

$153.95 /

+0.62 (+0.40%)

This is the first decline…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
CDC reports first U.S. coronavirus case of unknown origin, Bloomberg reports » 19:50
02/26/20
02/26
19:50
02/26/20
19:50
SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

Says the case has no ties…

Says the case has no ties to a known outbreak.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Forterra sees FY20 adj. EBITDA $210M-$240M vs. $203.9M in FY19 » 19:47
02/26/20
02/26
19:47
02/26/20
19:47
FRTA

Forterra

$14.24 /

-0.37 (-2.53%)

Sees FY20 capex…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Forterra reports Q4 EPS (12c), consensus (13c) » 19:45
02/26/20
02/26
19:45
02/26/20
19:45
FRTA

Forterra

$14.24 /

-0.37 (-2.53%)

Reports Q4 revenue…

Reports Q4 revenue $363.1M, consensus $346.91M. Reports Q4 adj. EBITDA $41.5M vs. $32.9M last year. Forterra CEO Karl Watson, Jr. commented, "Our fourth quarter results reflect another step forward in our journey to earning a full and fair return on the products we produce and the capital we have deployed. We had a solid finish to the year with increased volume in both of our businesses largely due to favorable weather, continued pricing improvements, and reduced scrap costs in our Water segment. These benefits were partially offset by higher operating expenses reflecting our investments in manufacturing activities to improve future operational efficiencies. As a result, we exceeded our annual earnings and debt reduction targets for the year."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Mack-Cali Realty sees FY20 core FFO $1.24-$1.36, consensus $1.45  19:43
02/26/20
02/26
19:43
02/26/20
19:43
CLI

Mack-Cali Realty

$20.05 /

-0.4 (-1.96%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Mack-Cali Realty reports Q4 FFO 44c, consensus 41c » 19:42
02/26/20
02/26
19:42
02/26/20
19:42
CLI

Mack-Cali Realty

$20.05 /

-0.4 (-1.96%)

Reports Q4 revenue…

Reports Q4 revenue $86.7M, consensus $136.76M. Reports Q4 same-store NOI up 3.5%. Michael DeMarco, CEO, stated, "In 2019, we achieved a number of important milestones, including the completion of over $2.1 billion of transactions and the launch of our final non-core disposition initiative. Waterfront office leasing, while slower than prior years, is beginning to show some improvement; and our residential properties continue to perform ahead of our expectations. Leasing and balance sheet management are top priorities in 2020 as we continue to work to maximize value for our shareholders."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
NiSource sells Columbia Gas of Massachusetts to Eversource » 19:36
02/26/20
02/26
19:36
02/26/20
19:36
NI

NiSource

$27.79 /

-0.6 (-2.11%)

, ES

Eversource

$93.45 /

-0.05 (-0.05%)

NiSource (NI) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
FDA advisory committee votes in favor of Eli Lilly's ramucirumab in NSCLC » 19:32
02/26/20
02/26
19:32
02/26/20
19:32
LLY

Eli Lilly

$133.47 /

-1.9 (-1.40%)

Eli Lilly announced that…

Eli Lilly announced that a FDA Oncologic Drugs Advisory Committee voted 6-5 that CYRAMZA, or ramucirumab, plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer, or NSCLC, based on the results of the positive Phase 3 RELAY study. The ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License Application currently under review by the FDA. In the RELAY study, CYRAMZA, a VEGF receptor 2 antagonist, in combination with erlotinib, a globally approved EGFR-targeting tyrosine kinase inhibitor, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival - the time patients live without their disease getting worse - compared to erlotinib alone. "Given the unmet need that remains in treating metastatic EGFR-mutated non-small cell lung cancer, we are encouraged that the majority of these experts agree CYRAMZA plus erlotinib has a favorable benefit/risk profile for the first-line treatment of these patients," said Maura Dickler, M.D., vice president of late phase development, Lilly Oncology. "We believe in the clinical meaningfulness of the data from the RELAY trial, which targeted the VEGFR and EGFR pathways together. We look forward to continuing to work with the FDA on this application to offer a new front-line treatment option for people with metastatic EGFR-mutated non-small cell lung cancer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Grupo Simec reports Q4 net loss MXN2.63B vs. profit MXN330M last year » 19:28
02/26/20
02/26
19:28
02/26/20
19:28
SIM

Grupo Simec

$9.85 /

+ (+0.00%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General News
Trump says he thinks stock market will recover  19:08
02/26/20
02/26
19:08
02/26/20
19:08
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Insight Enterprises announces $50M stock buyback » 19:07
02/26/20
02/26
19:07
02/26/20
19:07
NSIT

Insight Enterprises

$55.21 /

-0.46 (-0.83%)

Insight Enterprises…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General News
Trump says 'not the right time' for more South Korea, Italy travel restrictions  19:06
02/26/20
02/26
19:06
02/26/20
19:06
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:03
02/26/20
02/26
19:03
02/26/20
19:03
SPT

Sprout Social

$17.70 /

-1.11 (-5.90%)

, TDOC

Teladoc

$116.89 /

-1.55 (-1.31%)

, AKRX

Akorn

$1.29 /

-0.04 (-3.02%)

, ALIM

Alimera Sciences

$6.38 /

-0.06 (-0.93%)

, ETSY

Etsy

$50.64 /

+0.73 (+1.46%)

, ESTC

Elastic

$63.78 /

-2.235 (-3.39%)

, DDD

3D Systems

$10.24 /

-0.355 (-3.35%)

, BOX

Box

$14.98 /

-0.075 (-0.50%)

, NTRA

Natera

$34.76 /

-0.2 (-0.57%)

, CPE

Callon Petroleum

$2.21 /

-0.14 (-5.96%)

, UPWK

Upwork

$8.13 /

-0.19 (-2.28%)

, SQ

Square

$76.63 /

-0.38 (-0.49%)

, CLW

Clearwater Paper

$26.98 /

+0.71 (+2.70%)

, RUBI

Rubicon Project

$11.03 /

-0.6 (-5.16%)

, NDLS

Noodles & Company

$7.90 /

-0.35 (-4.24%)

, OPK

Opko Health

$1.39 /

-0.005 (-0.36%)

, ARNA

Arena Pharmaceuticals

$46.98 /

-0.93 (-1.94%)

, ACAD

Acadia

$40.30 /

-0.37 (-0.91%)

, SWX

Southwest Gas

$71.84 /

-2.02 (-2.73%)

, CLGX

CoreLogic

$48.39 /

+ (+0.00%)

, QGEN

Qiagen

$35.08 /

+0.09 (+0.26%)

, GILD

Gilead

$74.70 /

+4.57 (+6.52%)

, CLR

Continental Resources

$20.79 /

-1.125 (-5.13%)

, NTNX

Nutanix

$32.65 /

-2.08 (-5.99%)

, TPC

Tutor Perini

$11.99 /

+0.46 (+3.99%)

, QEP

QEP Resources

$2.16 /

-0.105 (-4.64%)

, MED

Medifast

$94.05 /

-1.09 (-1.15%)

, CVNA

Carvana

$101.66 /

-2.535 (-2.43%)

, LHCG

LHC Group

$150.40 /

+1.81 (+1.22%)

, FRGI

Fiesta Restaurant

$9.07 /

-0.91 (-9.12%)

, CCI

Crown Castle

$162.74 /

-0.33 (-0.20%)

, PTLA

Portola Pharmaceuticals

$12.51 /

-0.13 (-1.03%)

, PDCE

PDC Energy

$18.48 /

-1 (-5.13%)

, ANSS

Ansys

$273.00 /

+6.64 (+2.49%)

, SILK

Silk Road Medical

$45.25 /

-1.29 (-2.77%)

, RGNX

Regenxbio

$47.50 /

+0.13 (+0.27%)

, LB

L Brands

$22.77 /

-0.76 (-3.23%)

, NTES

NetEase

$345.55 /

+7.47 (+2.21%)

, BKNG

Booking Holdings

$1,683.38 /

-44.63 (-2.58%)

, MSFT

Microsoft

$170.20 /

+2.14 (+1.27%)

UP AFTER EARNINGS: Sprout…

UP AFTER EARNINGS: Sprout Social (SPT) up 18.6%... Teladoc (TDOC) up 17.2%... Akorn (AKRX) down 12.7%... Alimera Sciences (ALIM) up 11.5%... Etsy (ETSY) up 10.6%... Elastic (ESTC) up 10.5%... 3D Systems (DDD) up 9.2%... Box Inc (BOX) up 8.8%... Natera (NTRA) up 8.7%... Callon Petroleum (CPE) up 8.1%... Upwork (UPWK) up 8.0%... Square (SQ) up 7.4%... Clearwater Paper (CLW) up 5.6%... Rubicon Project (RUBI) up 5.5%... Noodles & Co (NDLS) up 5.4%... Opko Health (OPK) up 5.1%... Arena Pharma (ARNA) up 4.5%... Acadia Pharma (ACAD) up 4.1%... Southwest Gas (SWX) up 4.0%... Corelogic (CLGX) up 2.1%. ALSO HIGHER: Qiagen (QGEN) up 3.3% after announcing shipments of coronavirus test kits... Gilead (GILD) up 3.0% after initiating two phase 3 studies of antiviral Remdesivir in coronavirus. DOWN AFTER EARNINGS: Continental Resources (CLR) down 17.0%... Nutanix (NTNX) down 16.0%... Tutor Perini (TPC) down 15.8%... QEP Resources (QEP) down 14.8%... Medifast (MED) down 14.3%... Carvana (CVNA) down 10.7%... LHC Group (LHCG) down 6.9%... Fiesta Restaurant (FRGI) down 6.6%... Crown Castle (CCI) down 5.7%... Portola Pharma (PTLA) down 5.2%... PDC Energy (PDCE) down 5.0%... Ansys (ANSS) down 3.8%... Silk Road Medical (SILK) down 2.5%... Regenexbio (RGNX) down 2.3%... L Brands (LB) down 2.1%... NetEase (NTES) down 1.7%... Booking Holdings (BKNG) down 0.5%. ALSO LOWER: Microsoft (MSFT) down 1.4% after saying will not meet Q3 guidance in More Personal Computing segment. Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General News
CDC's Schuchat says expects more coronavirus cases in U.S. » 19:00
02/26/20
02/26
19:00
02/26/20
19:00
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

Speaking at a news…

Speaking at a news conference, CDC principal deputy director Anne Schuchat said that while the U.S.'s aggressive containment strategy around coronavirus has been working, she still expects more coronavirus cases in the U.S.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General News
POTUS puts VP Mike Pence in charge of U.S. coronavirus response  18:52
02/26/20
02/26
18:52
02/26/20
18:52
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$311.66 /

-1.04 (-0.33%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.